Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL11853077 | 0.98 | CA2 (0.32) | CA2CA12CA1CA9CHKA | |
| Hydrochloric Acid SCHEMBL27950022 | 0.96 | CA2 (0.31) | CA2CA12CA1CA9CHKA | |
| SCHEMBL28819425 | 0.92 | CA2 (0.32) | CA2CHKA | |
| SCHEMBL2165604 | 0.86 | — | — | |
| SCHEMBL29160731 | 0.86 | CA2 (0.33) | CA2CA12CA1CA9CHKA | |
| SCHEMBL29020766 | 0.85 | HRH4 (0.38) | — | |
| SCHEMBL225178 | 0.83 | FDPS (0.35) | — | |
| SCHEMBL29088717 | 0.83 | FDPS (0.35) | — | |
| SCHEMBL195407 | 0.82 | ANPEP (0.33) | CA2CA12CA1CA9CHKA | |
| SCHEMBL28306346 | 0.82 | CA2 (0.31) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1860 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011578-A | Fluorine-free halogen-free flame retardant polypropylene composition and preparation method and application thereof | 金发科技股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122011579-A | Fluorine-free halogen-free flame retardant polypropylene composition and preparation method and application thereof | 金发科技股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260115979-A1 | FOAM MATERIAL WITH THERMAL INSULATION, FLAME RESISTANCE AND EMI SHIELDING | INT AUTOMOTIVE COMPONENTS GROUP NA INC (US) | 2026-04-30 | — | — | US | claimed |
| CN-118620324-B | Halogen-free ablation-resistant polypropylene resin composition and application thereof | 金发科技股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| EP-4638573-A1 | FLAME RESISTANT FOAMED ARTICLE | SABIC Global Technologies B.V. (NL) | 2025-10-29 | — | — | EP | claimed |
| CN-120158029-A | Polypropylene composition and preparation method and application thereof | 金发科技股份有限公司 | 2025-06-17 | — | — | CN | claimed |
| US-20250188321-A1 | FIRE-RETARDANT PRESSURE SENSITIVE ADHESIVES, ARTICLES, AND USES | 3M INNOVATIVE PROPERTIES COMPANY | 2025-06-12 | — | — | US | claimed |
| CN-119928359-A | Polypropylene composite material and preparation method and application thereof | 成都金发科技新材料有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119775633-A | High-temperature yellowing-resistant piperazine pyrophosphate compound and preparation method thereof | 云南云天化股份有限公司 | 2025-04-08 | — | — | CN | claimed |
| EP-4526388-A1 | MOISTURE CURABLE COMPOSITION | Bostik SA (FR) | 2025-03-26 | — | — | EP | claimed |
| EP-1548076-A1 | Compositions and methods for low downforce pressure polishing of copper | Rohm and Haas Electronic Materials CMP Holdings, Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050136671-A1 | Compositions and methods for low downforce pressure polishing of copper | ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS, INC. | 2005-06-23 | — | — | US | claimed |
| US-20040209982-A1 | Foams expanding in a fire | INTUMEX GMBH (AT) | 2004-10-21 | — | — | US | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20030191078-A1 | Inhibition of infectious agents by exogenous oligonucleotides | HYBRIDON, INC. | 2003-10-09 | — | — | US | claimed |
| US-20030186911-A1 | Inhibition of infectious agents by exogenous oligonucleotides | HYBRIDON, INC. | 2003-10-02 | — | — | US | claimed |
| EP-0882091-A1 | UNSATURATED POLYESTER RESINS FLAME RETARDED BY MELAMINE AND PHOSPHORUS COMPOUNDS | DSM N.V. (NL) | 1998-12-09 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1997031056-A1 | UNSATURATED POLYESTER RESINS FLAME RETARDED BY MELAMINE AND PHOSPHORUS COMPOUNDS | DSM N.V. (NL) | 1997-08-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191078-A1 | Inhibition of infectious agents by exogenous oligonucleotides | EIF2AK2, DCLRE1B, DDX5 | CA2 4266/4885CA12 3417/4885CA1 4149/4885 |
| US-20030186911-A1 | Inhibition of infectious agents by exogenous oligonucleotides | EIF2AK2, HAVCR2, SARS1 | CA2 4230/4885CA12 2697/4885CA1 3747/4885 |
| US-20260115979-A1 | FOAM MATERIAL WITH THERMAL INSULATION, FLAME RESISTANCE AND EMI SHIELDING | FLI1, MIF, RFT1 | CA2 4812/4885CA12 4514/4885CA1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.